Compare Bristol-Myers Squibb Co (BMY) vs ProShares UltraShort Bloomberg Natural Gas ETF (KOLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs ProShares UltraShort Bloomberg Natural Gas ETF — how do they compare? Bristol-Myers Squibb Co trades at $57 (market cap $116.30B), while ProShares UltraShort Bloomberg Natural Gas ETF trades at $27.54. The key difference: Bristol-Myers Squibb Co pays a 4.42% dividend while ProShares UltraShort Bloomberg Natural Gas ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, ProShares UltraShort Bloomberg Natural Gas ETF nearer its low. Which is the better fit depends on your goals.
| BMY | KOLD | |
|---|---|---|
Market Cap | $116.30B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $62.37 | $49.39 |
52-Week Low | $42.60 | $13.58 |
Enterprise Value | $152.24B | — |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
KOLD, the ProShares UltraShort Bloomberg Natural Gas ETF, trades at $27.98, up 3.78% on the day. Technical indicators show a bullish trend with strong moving average support, though RSI levels suggest overbought conditions. Recent news highlights volatility in natural gas futures driven by weather forecasts and LNG demand, with the ETF positioned as a tactical trading tool amid price swings around $3/MMBtu. The overall technical signal is bullish, but oscillators remain neutral, indicating potential near-term consolidation.
The outlook for KOLD is tied to natural gas price volatility, with opportunities for short-term gains if gas prices decline due to rising supply or milder weather. Key risks include unexpected demand spikes from heat waves or geopolitical events, which could pressure the inverse ETF. Investors should monitor EIA storage reports and weather trends closely, as these are primary catalysts for movement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About ProShares UltraShort Bloomberg Natural Gas ETF
KOLD is an inverse leveraged ETF that seeks to provide two times (2x) the inverse daily performance of the Bloomberg Natural Gas Subindex. It is designed for investors looking to profit from falling natural gas prices.
Read more on KOLD →
